Est' li vozmozhnost' snizit' risk razvitiya NPVP-gastropatii?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used class of pharmacological agents. They allow treating acute pain and controlling chronic pain; so, they are often appointed by a variety of specialists. Almost since the introduction of this class of drugs in clinical practice, doctors are aware of the fact that the positive effects of these drugs are associated with a number of side effects, and one of the most serious side effects is the damage of gastrointestinal tract and the development of bleeding. Pharmacologists had several attempts to create a NSAIDs that do not have side effects on the gastrointestinal tract. The article presents a new non-selective NSAID, amtolmetin guacil, and the the mechanism of its action. Gastroprotective properties of the drug associated with increased concentration of nitrogen oxide in the gastric mucosa are emphasized. The data of the efficacy and safety compared to other NSAIDs are discussed.

Full Text

Restricted Access

About the authors

O. V Yakob

Email: oyakob@yandex.ru

References

  1. Pasero G., Marson P. A short history of antirheumatic therapy. II. Aspirin // Reumatismo. - 2010. - Vol. 62(2). - P. 148-56.
  2. Brune K. The early history of non-opioid analgesics // Acute Pain. - 1997. - Vol. 1. -P. 33-40.
  3. Italian Medicines Agency, OsMed Working Group. The use of drugs in Italy. National report in 2008 [report in Italian], 2009. - P. 8-12.
  4. Карасева Г.А. НПВП-индуцированная гастропатия: от понимания механизмов развития к разработке стратегии профилактики и лечения // Медицинские новости. - 2012. - № 8. - С. 21-6.
  5. Tulassay Z., Herszenyi L. Gastric mucosal defense and cytoprotection // Best Practice & Res. Clin. Gastroenterol. - 2010. - Vol. 24. - P. 99-108.
  6. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond//J. Pharm. Pharm. Sei. - 2008. - Vol. 11(2). - 81s-110s.
  7. Rainsford K.D. Anti-inflammatory drugs in the 21st century // Subcell. Biochem. - 2007. - Vol. 42. - P. 3-27.
  8. Scarpignato C., Hunt R.H. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention // Gastroenterol. Clin. North Am. - 2010. - Vol. 39. - P. 433-64.
  9. Helin-Salmivaara A., Saarelainen S., Gronroos J., et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population // Scan. J. Gastroenterol. - 2007. - Vol. 42. -P. 923-32.
  10. Roth S.H. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety // Clin. interven. Aging. - 2011. - Vol. 6. - P. 125-31.
  11. Лапина Т.Л. Гастропатия индуцированная нестероидными противовоспалительными препаратами:пути решения// РМЖ. - 2009. - № 2. - С. 54-8.
  12. Лапина Т.Л. Пути снижения гастроинтестинального риска при назначении нестероидных противовоспалительных препаратов // Consilium medicum. - 2013. -№ 2. - С. 50-2.
  13. Rostom A., Dube C., Wells G.A, et al. Prevention of NSAID-induced gastroduodenal ulcers // Cochrane Database Systematic Reviews. -2002. - Issue 4. Art No.:CD002296. doi: 10.1002/14651858. CD002296.
  14. Castellsague J., Pisa F., Rosolen V., et al. pharmacoepidemiology and drug safety 2012 Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ pds.3385
  15. Rostom A., Muir K., Dube C., et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review // Clin. Gastroenterol. Hepatol. - 2007. - Vol. 5(7). - P. 818-28.
  16. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al.; Investigators of the Asociacion Espanola de Gastroenterologia (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants // Am. J. Gastroenterol. - 2007. - Vol. 102. - P. 507-15.
  17. Piazuelo E., Fuentes J., Garcfa-Gonzalez M.A., et al. A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin // Clin. Ther. - 2008. - Vol. 30. -P. 121-30.
  18. Borhade N., Pathan A.R., Halder S., et al. NO-NSAIDs. Part 3: Nitric Oxide-Releasing Prodrugs of Non-steroidal Anti-inflammatory Drugs // Chem. Pharm. Bull. - 2012. - Vol. 60(4). - P. 465-81.
  19. Ивашкин В.Т., Драпкина О.М. Клиническое значение оксида азота и белков теплового шока. М., 2011. - С. 376.
  20. Brzozowski T., et al. Role of prostaglandins in gastroprotection and gastric adaptation // J. Physiol. Pharmacol. - 2005. - Vol. 56(Suppl. 5). -P. 33-55.
  21. Qandil A.M. Prodrugs of Nonsteroidal Anti- Inflammatory Drugs (NSAIDs), More Than Meets the Eye: A Critical ReviewInt // J. Mol. Sci. - 2012. - Vol. 13. - P. 17244-74.
  22. Petazzi I, Corberi G, Bonollo L, et al. Clinical study of the therapeutic activity and tolerabil-ity of artromed in comparison with naproxen in patients with osteoarthritis in different localizations //Drugs Exp. Clin. Res. - 1990. - Vol. 16. -P. 25-30.
  23. Tubaro E., Belogi L., Mezzadri C.M. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug // Eur. J. Pharmacol. - 2000. - Vol. 387. - P. 233-44.
  24. Jajic Z., Malaise M., Nekam K., et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis// Clin. Experiment Rheumatol. - 2005. - Vol. 23. - P. 809-18.
  25. Riezzo G., Chiloiro M., Montanaro S. Protective effects of amtometin guacyl verus placebo diclofenac and mioprostol in healthy volunteers evaluated as gastric electrical activity in alcohol-induced stomach damage // Dig. Dis. Sci. - 2001. - Vol. 46. - P.1797-804.
  26. Pisano C., Grandi D., Morini G., et al. Gastrosparing effect of the new antiinflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxide // Dig. Dis. Sci. - 1999. - Vol. 44(4). - P. 713-24.
  27. Kirkova M., Kesiova M., Konstantinova S., et al. In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems in different models of gastrointestinal injury // Autonomic & Autacoid Pharmacology. - 2007. - Vol. 27. - P. 63-70.
  28. Petazzi I., Corberi G., Bonollo L., et al. Evaluation of the time course of the algic-inflammatory symptoms in patients with osteoarthritic afflictions during and after treatment with artromed or diclofenac // Drugs Exp. Clin. Res. - 1990. - Vol. 16. - P. 7-12.
  29. Marcolongo R., Frediani B., Biasi G., et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal AntiInflammatory Drug, Compared with Established Agents // Clin. Drug. Invest. - 1999. - Vol. 17(2). - P. 89-96.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies